Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Rubitecan in Relapsed NSCLC
NCT00005872Phase 2Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- May 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rubitecan in non-small cell lung cancer (NSCLC), sponsored by Astex Pharmaceuticals. Started May 1999; status: completed.
02
Drugs
rubitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00005872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005872.